IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 'MONTPARK' Clinical Trial -April 08, 2024 at 07:45 am EDT : vimarsana.com

SAINT LAURENT, Quebec, April 08, 2024 -- IntelGenx Corp.  today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease patients in the Phase 2 clinical...

Related Keywords

Sweden , Quebec , Canada , United States , Saint Laurent , Canadian , Swedish , Dwight Gorham , Stephen Kilmer , Andre Godin , Montelukast Versafilm , Exchange Commission , Intelgenx Corp , Drug Administration , Swedish University , Intelgenx Technologies Corp , World Health Organization , Parkinson Foundation , Securities Exchange , Karolinska University Hospital , Company Or Intelgenx , Per Svenningsson , Lead Principal , Health Organization , Leukotriene Receptor Antagonist Montelukast , Looking Information , Securities Exchange Act , Securities Act , United States Securities , Intelgenx Technologies , Markets ,